Form 8-K - Current report:
SEC Accession No. 0001356576-25-000015
Filing Date
2025-02-25
Accepted
2025-02-25 16:06:45
Documents
15
Period of Report
2025-02-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K supn-20250225.htm   iXBRL 8-K 33474
2 EX-99.1 ex991earningsrelease.htm EX-99.1 226075
6 GRAPHIC supernuslogoa.jpg GRAPHIC 19991
  Complete submission text file 0001356576-25-000015.txt   432361

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT supn-20250225.xsd EX-101.SCH 1798
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT supn-20250225_lab.xml EX-101.LAB 21884
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT supn-20250225_pre.xml EX-101.PRE 12522
17 EXTRACTED XBRL INSTANCE DOCUMENT supn-20250225_htm.xml XML 2727
Mailing Address 9715 KEY WEST AVENUE ROCKVILLE MD 20850
Business Address 9715 KEY WEST AVENUE ROCKVILLE MD 20850 301-838-2500
SUPERNUS PHARMACEUTICALS, INC. (Filer) CIK: 0001356576 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35518 | Film No.: 25663049
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)